Voyager Therapeutics, Inc.
NASDAQ:VYGRBiotechnology
+$0.09 today
- Market cap
- $103.92M
- Beta
- 1.25
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$1.96
Volume 0.84M
Average 0.54M
VYGR Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Voyager Therapeutics, Inc.NASDAQ: VYGR
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $2.49M fell 32.3% year over year, behind the -8.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 29.3% from the prior quarter. Over 3 fiscal years it compounded at +16.5% a year.
Context
- Stock-based compensation amounted to 36.6% of revenue in FY2025, up 18.1 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -32.3% toward the trailing-twelve-month pace of -8.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 14.79M USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +6.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.79M | +0.0% |
| FY2024 | 2024-12-31 | 14.79M | +32.6% |
| FY2023 | 2023-12-31 | 11.15M | +19.4% |
| FY2022 | 2022-12-31 | 9.34M | -17.5% |
| FY2021 | 2021-12-31 | 11.32M | — |
Stock-Based Compensation vs competitors
How VYGR compares with its peers on the latest reported figures
- VYGR's LTM Mar 2026 stock-based compensation of $13.6M is the 6th largest of the 11 companies compared; the peer median is $13.1M.
- Its year-over-year change of -8.6% is the 5th highest of 11, against a peer median of -28.1%.
- Stock-based compensation amounts to 37.3% of revenue for VYGR, versus a peer median of 54.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.74M | -35.1% | -23.4% | — | |
| LTM Mar 2026 | $23.07M | -33.2% | -6.0% | 50.9% | |
| LTM Mar 2026 | $19.27M | -0.0% | +25.6% | 335.8% | |
| LTM Mar 2026 | $17.5M | -62.1% | -23.7% | — | |
| LTM Mar 2026 | $15.77M | -32.9% | -11.7% | 22.8% | |
| LTM Mar 2026 | $13.6M | -8.6% | +16.5% | 37.3% | |
| LTM Mar 2026 | $10.44M | +45.6% | +16.4% | 517.7% | |
| LTM Mar 2026 | $9.07M | -23.3% | -16.5% | 4.2% | |
| LTM Mar 2026 | $8.17M | -33.3% | -9.2% | 59.0% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $6.82M | +13.6% | +50.8% | — |
| LTM Mar 2026 | $5.84M | -6.8% | +38.9% | — | |
| Peer median (excluding VYGR) | $13.1M | -28.1% | -7.6% | 54.9% | |
Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.2M) | (46.41M) | 132.33M | (65M) | (119.72M) |
| Depreciation & Amortization | 5.17M | 6.19M | 4.44M | 4.73M | 4.06M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.32M | 9.34M | 11.15M | 14.79M | 14.79M |
| Change in Working Capital | 3.29M | 20.47M | (66.56M) | 34.86M | (28.76M) |
| Accounts Receivables | 7.28M | 475K | (83.23M) | 81.31M | 268K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (60K) | 1.99M | (962K) | 2.39M | 1.02M |
| Other Working Capital | (3.93M) | 18M | 17.64M | (48.84M) | (30.05M) |
| Other Non-Cash Items | (2.11M) | (2.11M) | (3.45M) | (4.68M) | (2.83M) |
| Operating Cash Flow | (53.53M) | (12.51M) | 77.92M | (15.31M) | (132.47M) |
| Capital Expenditures | (1.61M) | (2.49M) | (3.26M) | (3.52M) | (2.6M) |
| Acquisitions (Net) | 0 | 0 | 138.39M | 0 | 0 |
| Purchases of Investments | (15.12M) | (54.85M) | (223.97M) | (465.69M) | (133.93M) |
| Sales of Investments | 82.63M | 50M | 85.58M | 374.35M | 261.97M |
| Other Investing Activities | 0 | 0 | (138.39M) | 0 | 0 |
| Investing Cash Flow | 65.91M | (7.34M) | (141.64M) | (94.86M) | 125.45M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 612K | 1.11M | 33.65M | 114.02M | 816K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 612K | 1.11M | 33.65M | 114.02M | 816K |
| Effect of Forex Changes | 0 | 264K | 0 | 0 | 0 |
| Net Change in Cash | 12.99M | (18.47M) | (30.08M) | 3.85M | (6.21M) |
| Free Cash Flow | (55.13M) | (15M) | 74.66M | (18.83M) | (135.06M) |
Voyager Therapeutics, Inc.
NASDAQ:VYGR
Intrinsic Alpha fair value
Locked
Current Price
$1.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.